Ph III randomized studies of the oral pan-PI3K inhibitor buparlisib (BKM120) with fulvestrant in postmenopausal women with HR+/HER2- locally advanced or metastatic breast cancer (BC) after aromatase inhibitor (AI; BELLE-2) or AI and mTOR inhibitor (BELLE-3) treatment Meeting Abstract


Authors: Iwata, H.; Baselga, J.; Campone, M.; Arteaga, C. L.; Cortes, J.; Jonat, W.; De Laurentiis, M.; Ciruelos, E.; Janni, W.; Bachelot, T.; Lonning, P. E.; Ma, C.; O'Regan, R.; Di Tomaso, E.; Bharani-Dharan, B.; Duval, V.; Lau, H.; Germa, C.; Urban, P.; Di Leo, A.
Abstract Title: Ph III randomized studies of the oral pan-PI3K inhibitor buparlisib (BKM120) with fulvestrant in postmenopausal women with HR+/HER2- locally advanced or metastatic breast cancer (BC) after aromatase inhibitor (AI; BELLE-2) or AI and mTOR inhibitor (BELLE-3) treatment
Meeting Title: 49th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 31
Issue: 15 Suppl.
Meeting Dates: 2013 May 31-Jun 4
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2013-05-20
Language: English
ACCESSION: WOS:000335419605480
PROVIDER: wos
Notes: Meeting Abstract: TPS650^ -- Source: Wos